There's a constant flux of new investor's. i.e. According to this list of Lexaria's Institutional Holdings, Invenomic Capital management currently owns 359,113 shares.
I imagine that as the hopefully good news on FDA phases 1 and 2 are announced for the CBD indications for NDI's that the new institutional investors action should heat up. I would have liked to see things happen faster just like anyone but the groups with the big bucks are the ones controlling the SP and obviously the move to Big Pharma is a longer road than making puny royalty deals with Mom and Pop shops.
As far as a company partnering up with Lexaria, this would be the worst time for that with the SP at ATL. Better to give a partner 10% of the company at 100M cap than 50% of the company at 20M cap.
News 
Market Data 
Discover 
AI
